DK0958821T3 - Fedtemulsion, der indeholder xanthinderivat - Google Patents

Fedtemulsion, der indeholder xanthinderivat

Info

Publication number
DK0958821T3
DK0958821T3 DK97934737T DK97934737T DK0958821T3 DK 0958821 T3 DK0958821 T3 DK 0958821T3 DK 97934737 T DK97934737 T DK 97934737T DK 97934737 T DK97934737 T DK 97934737T DK 0958821 T3 DK0958821 T3 DK 0958821T3
Authority
DK
Denmark
Prior art keywords
fat emulsion
xanthine derivative
emulsion containing
containing xanthine
hydroxyl
Prior art date
Application number
DK97934737T
Other languages
English (en)
Inventor
Toshihito Hosokawa
Kenji Iwata
Yuji Kawaguchi
Yasuki Kato
Kunio Ito
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of DK0958821T3 publication Critical patent/DK0958821T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Edible Oils And Fats (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Colloid Chemistry (AREA)
DK97934737T 1996-08-07 1997-08-07 Fedtemulsion, der indeholder xanthinderivat DK0958821T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22439996 1996-08-07
EP97934737A EP0958821B1 (en) 1996-08-07 1997-08-07 Fat emulsion containing xanthine derivative

Publications (1)

Publication Number Publication Date
DK0958821T3 true DK0958821T3 (da) 2005-01-03

Family

ID=16813150

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97934737T DK0958821T3 (da) 1996-08-07 1997-08-07 Fedtemulsion, der indeholder xanthinderivat

Country Status (15)

Country Link
US (1) US6210687B1 (da)
EP (1) EP0958821B1 (da)
JP (2) JP4179631B2 (da)
KR (1) KR20000029672A (da)
CN (1) CN1227490A (da)
AT (1) ATE281835T1 (da)
AU (1) AU3784597A (da)
CA (1) CA2262578A1 (da)
DE (1) DE69731556T2 (da)
DK (1) DK0958821T3 (da)
ES (1) ES2232877T3 (da)
NZ (1) NZ334299A (da)
PT (1) PT958821E (da)
SI (1) SI0958821T1 (da)
WO (1) WO1998005334A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123538A1 (en) * 2000-12-29 2002-09-05 Peiguang Zhou Hot-melt adhesive based on blend of amorphous and crystalline polymers for multilayer bonding
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
MXPA05011371A (es) 2003-04-25 2005-12-01 Novacardia Inc Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
EP1932529A1 (en) 2003-04-25 2008-06-18 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
BRPI0509753A (pt) * 2004-04-16 2007-10-16 Novacardia Inc composição farmacêutica e método de tratamento de doença cardiovascular
EP1928414A2 (en) * 2005-04-22 2008-06-11 Novacardia, Inc. Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions
PL1915156T3 (pl) * 2005-08-15 2012-12-31 Provimi Holding B V Zastosowanie środków pobudzających psychomotorycznie i zawierających je kompozycji w sposobie leczenia rodzących ssaków łożyskowych w celu zmniejszenia wycieńczenia matki i/lub macicy
US7893070B2 (en) 2005-08-15 2011-02-22 Provimi Holding B.V. Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion
JPWO2007069675A1 (ja) * 2005-12-14 2009-05-28 協和発酵キリン株式会社 キサンチン誘導体の易吸収性経口製剤
AU2007235372A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine A1 receptor antagonists and anticonvulsants
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
EP2627173B2 (en) 2010-10-12 2018-07-04 Chiesi Farmaceutici S.p.A. Clevidipine emulsion formulations containing antimicrobial agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146621A (en) * 1973-01-16 1979-03-27 The Regents Of The University Of Michigan Process of treating proliferative skin diseases
JPH0647533B2 (ja) * 1984-08-10 1994-06-22 裕 水島 4−ビフエニリル酢酸系化合物含有脂肪乳剤
ES2039219T3 (es) * 1986-08-11 1993-09-16 American Cyanamid Company Composiciones para administracion parenteral y su uso.
JPH0559056A (ja) * 1991-02-25 1993-03-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
WO1994016702A1 (fr) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
JPH07285863A (ja) * 1994-02-25 1995-10-31 Takeda Chem Ind Ltd 注射剤組成物およびその製造方法
JPH0881360A (ja) * 1994-07-13 1996-03-26 Wakamoto Pharmaceut Co Ltd 安定な脂肪乳剤
JP4008965B2 (ja) * 1994-07-29 2007-11-14 昭和産業株式会社 レシチン含有脂肪乳剤の調製法
JPH08104620A (ja) * 1994-10-05 1996-04-23 Green Cross Corp:The 薬物含有脂肪乳剤

Also Published As

Publication number Publication date
AU3784597A (en) 1998-02-25
DE69731556D1 (de) 2004-12-16
EP0958821A1 (en) 1999-11-24
JP4179631B2 (ja) 2008-11-12
EP0958821B1 (en) 2004-11-10
ATE281835T1 (de) 2004-11-15
JP2008231117A (ja) 2008-10-02
ES2232877T3 (es) 2005-06-01
KR20000029672A (ko) 2000-05-25
NZ334299A (en) 1999-05-28
CA2262578A1 (en) 1998-02-12
CN1227490A (zh) 1999-09-01
EP0958821A4 (en) 2003-05-02
WO1998005334A1 (fr) 1998-02-12
SI0958821T1 (en) 2005-02-28
PT958821E (pt) 2005-02-28
US6210687B1 (en) 2001-04-03
DE69731556T2 (de) 2005-10-27

Similar Documents

Publication Publication Date Title
DE69628276D1 (de) Zubereitung von xanthinderivaten als feste dispersion
DK0958821T3 (da) Fedtemulsion, der indeholder xanthinderivat
PT705833E (pt) Derivado de dc-89
ATE282630T1 (de) Dolastatin-derivate
DE69813605D1 (de) Benzofuranderivate
FI953710A0 (fi) Uusia pyrrolokarbatsoleja
SI1454903T1 (sl) Tiadiazolinski derivati za zdravljenje raka
PT947504E (pt) Derivados de vitamina d 16-eno
SE8502073D0 (sv) Delta?722-1,2,4-triazolin-5-on-derivat och herbicida kompositioner, som innehaller desamma
EP1031556A4 (en) 2-PHENOXYANILINE DERIVATIVES
ATE105565T1 (de) Pradimicinderivate.
DK0526840T3 (da) Kondenserede napthyridinderivater
DE69231244D1 (de) Pyrazolothiazolopyrimidin-derivate
DK0661273T3 (da) Indanderivater og fremgangsmåder til fremstilling af samme
KR890005110A (ko) 신규의 3-아로일-6,7-디히드로-5h-피롤로[1,2-c]이미다졸-7-카르복시산유도체
EP0614897A4 (en) IMIDAZONAPHTHYRIDINE DERIVATIVE.
KR880001578A (ko) 안식향산 유도체
KR860006209A (ko) 제초제 조성물